Fort Mill, S.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received notification from the Unites States Patent and Trademark Office for issuance of a new a VIVO patent titled Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model. This patent is in addition to several already granted patents for VIVO. ...

Core Insights - Catheter Precision, Inc. has announced new clinical data regarding its VIVO product, a non-invasive mapping system for identifying areas of ventricular arrhythmia, which shows over 95% accuracy and a reduction in procedure time by nearly 30% [2][4]. Company Overview - Catheter Precision is a US-based medical device company focused on developing advanced solutions for cardiac arrhythmias, collaborating with physicians to enhance electrophysiology procedures [6]. Product Details - VIVO (View Into Ventricular Onset) is a non-invasive 3D imaging system that helps physicians identify the origin of ventricular arrhythmias before procedures, thereby streamlining workflow and reducing procedure time. It has received marketing clearance from the U.S. FDA and holds the CE Mark [5]. Clinical Data Highlights - New clinical data indicates that VIVO not only functions as intended but may also improve patient outcomes, with significant reductions in procedure time and less burden of ventricular tachycardia (VT) during procedures [4]. - The data is being prepared for submission to industry journals for further detailed publication [3]. Expert Contributions - The new data has been compiled and presented by leading industry physicians, including Professor Sabine Ernst, Professor Tarv Dhanjal, and Dr. Dhanunjaya Lakkireddy [2].